U.S. Pharma Stock News

Sprinklr (NYSE:CXM) has launched its Spring 2026 Release, introducing advanced AI-driven features for its customer experience platform. The release adds autonomous agent evaluation tools designed to assess and monitor AI performance in customer service. Sprinklr also announced a new alliance with CreatorIQ to integrate creator intelligence with its unified social media management capabilities. Sprinklr enters this product release cycle with its shares at $4.84 and a value score of 2,...

Recent performance context for Campbell's Campbell's (CPB) has drawn attention after a period where the stock showed a small move over the past week, along with a sharper negative total return over the past 3 months and year. See our latest analysis for Campbell's. At a share price of $20.96, Campbell's recent 7 day and 30 day share price returns have been broadly flat, while the 90 day share price return of a 21.76% decline and 1 year total shareholder return of a 39.57% loss point to fading...

ZORYVE (roflumilast) cream has received a strong, high certainty recommendation in the American Academy of Dermatology’s new pediatric atopic dermatitis guidelines. This is the AAD’s first set of clinical practice guidelines focused on pediatric atopic dermatitis, giving the product formal visibility in a key treatment area. The endorsement supports ZORYVE’s role as an evidence backed option for long term use in children with atopic dermatitis. For Arcutis Biotherapeutics (NasdaqGS:ARQT),...

CME Group (NasdaqGS:CME) reported record average daily volumes and record revenues in Q1 2026. All six asset classes on the platform reached record activity levels in the quarter. The company is rolling out new options on Eris SOFR Swap futures and expanding Equity Index Dividend futures. Regulators approved an expanded cross margining arrangement with DTCC for U.S. Treasury and interest rate derivatives. CME Group sits at the center of global futures and options trading, connecting clients...

Heartland Express (HTLD) opened 2026 with Q1 results that extend a run of soft profitability, capped by trailing 12 month revenue of US$805.7 million and a basic EPS loss of US$0.67 tied to a net loss of US$52.5 million. Over the past six reported quarters, quarterly revenue has ranged from US$179.4 million to US$259.9 million, while basic EPS has moved between a loss of US$0.02 and a loss of US$0.25. This sets up a story where investors are weighing ongoing losses against forecasts that...

Shopify (SHOP) is back in focus as fresh commentary around its upcoming Q1 report highlights solid gross merchandise value trends, merchant growth, and heavier use of its tools, drawing renewed attention to the stock’s recent pullback. See our latest analysis for Shopify. At a share price of $124.23, Shopify has seen a 1-day share price return of 5.86% decline and a year to date share price return of 20.97% decline. However, the 1-year total shareholder return of 30.60% and 3-year total...

Martin Midstream Partners (MMLP) opened 2026 with Q1 results that keep the focus squarely on profitability, as the latest trailing 12 month figures show total revenue of US$716.1 million and a loss of US$14.4 million, or basic EPS of US$0.37. Over recent quarters, the partnership has seen quarterly revenue range from US$168.7 million to US$192.5 million, while basic EPS has moved between a profit of US$0.09 and losses of up to US$0.21. This sets up an earnings release where investors are...

Rezolve AI (RZLV) drew fresh attention after announcing its brainpowa commerce-tuned AI model suite is now available within Microsoft Foundry, giving brands access to commerce-focused copilots deployed directly on Microsoft Azure. See our latest analysis for Rezolve AI. Despite the Microsoft Foundry news and a last close of $2.60, Rezolve AI’s recent momentum has been mixed, with a 1-month share price return of 1.17% but a 90-day share price decline of 17.20%, alongside a 1-year total...

Lake Shore Bancorp (LSBK) has just wrapped up Q4 2025 with total revenue of US$7.3 million, basic EPS of US$0.26 and net income of US$1.9 million, while trailing twelve month figures show revenue of US$28.0 million and EPS of US$0.97, alongside 47.4% earnings growth over the past year. Over recent quarters, the company has seen revenue move from US$6.4 million and EPS of US$0.17 in Q3 2024 to US$7.7 million and EPS of US$0.32 in Q3 2025, before settling at Q4 2025 levels. This progression...

Origin Bancorp (OBK) has just posted Q1 2026 results with revenue of US$99.1 million and Basic EPS of US$0.89, setting the tone for how the year is starting after a run of solid quarterly contributions to trailing 12 month EPS of US$2.60 and net income of US$80.5 million. Over recent quarters, revenue has moved from US$83.4 million in Q4 2024 to US$90.6 million in Q1 2025 and US$99.8 million in Q4 2025. Quarterly Basic EPS has ranged from US$0.46 to US$0.95 across that same stretch, giving a...

Inhibrx Biosciences recently reported updated interim Phase 1/2 data showing that ozekibart (INBRX-109) plus FOLFIRI achieved a 20% objective response rate, 87% disease control rate, and manageable safety in heavily pretreated patients with unresectable colorectal cancer, while also advancing a Biologics License Application for ozekibart in conventional chondrosarcoma. These data position ozekibart as a potential first-in-class DR5 agonist with activity across multiple hard-to-treat solid...

Popular (BPOP) has just posted another solid quarter, with Q4 2025 revenue of US$751.8 million and basic EPS of US$3.54, setting the tone as investors look at the new Q1 2026 reporting period. The bank has seen quarterly revenue move from US$689.4 million in Q4 2024 to US$751.8 million in Q4 2025, while basic EPS over that same stretch climbed from US$2.51 to US$3.54, giving you a clear sense of how the income line has scaled alongside the top line. Taken together with an improved net profit...

Katahdin Bankshares (KTHN) has just put another quarter on the board, with Q4 2025 revenue of US$11.9 million and basic EPS of US$0.99 setting the tone after a year in which trailing net income reached US$10.7 million on revenue of US$44.3 million. Over recent periods the company has seen revenue move from US$9.5 million and EPS of roughly US$0.56 in Q4 2024 to US$11.9 million and US$0.99 respectively in Q4 2025. Trailing basic EPS for the last reported twelve months reached about US$3.37...

American Riviera Bancorp (ARBV) opened 2026 with Q1 results that build on a solid finish to last year, with Q4 2025 revenue at about US$14.4 million and basic EPS of roughly US$0.80, while trailing twelve month revenue stood at about US$50.4 million and EPS at roughly US$2.18. Over recent quarters, revenue has moved from about US$10.7 million in Q4 2024 to US$14.4 million in Q4 2025, and basic EPS has shifted from roughly US$0.35 to US$0.80. This sets up a story where higher net income and...

Recently, Surgery Partners reduced its earnings guidance after encountering slower surgical case growth, a less favorable payer mix, and reimbursement pressures across its facilities. An important angle is that the company is still prioritizing higher-acuity procedures and robotics investments, suggesting a focus on reshaping its case mix despite these operational challenges. We’ll now explore how this guidance cut, driven by slower case growth and payer mix headwinds, affects Surgery...

Medpace Holdings (MEDP) has followed up its recent run of strong results with Q4 2025 revenue of US$708.5 million and basic EPS of US$4.78, backing that up with trailing 12 month revenue of about US$2.5 billion and EPS of US$15.64. Over recent quarters the company has seen revenue move from US$533.3 million in Q3 2024 to US$708.5 million in Q4 2025, while quarterly basic EPS has ranged from US$3.11 to US$4.78 across the same stretch. With trailing net profit margins at 17.8% versus 19.2% the...

Mesabi Trust (MSB) has put fresh FY 2026 numbers on the table, with third quarter revenue of US$3.6 million, basic EPS of US$0.21 and net income of US$2.8 million. The trust has seen quarterly revenue move between US$4.7 million and US$6.9 million and EPS range from US$0.28 to US$0.46 over the past year of reported periods, alongside net income between US$3.6 million and US$6.1 million. This sets a clear context for the latest print. With a trailing net margin of 82.8% and earnings quality...

Farmers & Merchants Bancorp (FMAO) has put fresh numbers on the board, with Q4 2025 revenue of about US$31.9 million and basic EPS of US$0.70, supported by net income of US$9.7 million as the latest marker ahead of its Q1 2026 reporting period. The business has seen revenue move from US$26.6 million and EPS of US$0.59 in Q4 2024 to US$31.9 million and EPS of US$0.70 in Q4 2025. Trailing 12 month earnings growth of 29.4% and a 27.6% net margin frame a profitability profile that many investors...

Southern Missouri Bancorp (SMBC) opened Q3 2026 with Q2 results that put revenue and earnings in clear focus, reporting total revenue of US$48.0 million and basic EPS of US$1.62 on net income of US$18.1 million. The company has seen revenue move from US$41.7 million with EPS of US$1.10 in Q1 2025 to US$45.1 million and EPS of US$1.40 in Q4 2025, then to US$48.0 million and EPS of US$1.62 in Q2 2026. This latest report can be viewed as part of a steady earnings story that investors can now...

Carter Bankshares (CARE) opened Q1 2026 reporting Total Revenue of US$42.1 million in Q4 2025 and Basic EPS of US$0.38, with trailing twelve month EPS at US$1.38 and net income of US$31.0 million framing the latest run rate. Over the past year, Total Revenue on a trailing basis has moved from US$140.9 million to US$157.1 million while Basic EPS has shifted from US$1.06 to US$1.38, alongside earnings growth of 27.7% and net profit margin stepping up from 17.2% to 19.7%. For investors, these...

Republic Bancorp (RBCA.A) set the tone for Q1 2026 with recent results that sit against a trailing twelve month backdrop of US$385.9 million in revenue and basic EPS of US$6.65, underpinned by net income of US$131.3 million. Over the last few quarters, revenue has ranged from US$76.6 million to US$118.2 million per quarter while basic EPS moved between US$0.97 and US$2.40, giving investors a clear view of how the top and bottom lines have trended into the latest release. With a 34% net profit...

ONE Gas (OGS) has drawn fresh attention after its recent trading session, with the stock closing at $88.76. For investors, the move brings added focus to how the regulated utility’s fundamentals line up. See our latest analysis for ONE Gas. The latest move to $88.76 comes after a 14.93% 90 day share price return and a 16.97% total shareholder return over the past year, hinting that momentum has been building rather than fading. If this kind of steady utility performance has you thinking about...

MarineMax (HZO) has just posted its latest quarterly results, with Q1 2026 revenue of US$505.2 million and a basic EPS loss of US$0.36, alongside same store sales growth of 10.7%. The company has reported revenue of US$563.1 million in Q4 2024, US$631.5 million in Q2 2025, US$657.2 million in Q3 2025, US$552.2 million in Q4 2025, and US$505.2 million in Q1 2026, while EPS has ranged from a profit of US$0.80 in Q1 2025 to a loss of US$2.42 in Q3 2025. Margins remain under pressure, so this...

Thermo Fisher Scientific (TMO) has just put fresh numbers on the table, with Q4 2025 revenue of US$12.2b and basic EPS of US$5.22 setting the tone against a trailing twelve month EPS of US$17.78 on revenue of US$44.6b, alongside net income of US$6.7b. The company has seen quarterly revenue move from US$10.6b in Q3 2024 to US$12.2b in Q4 2025, while basic EPS over the same period went from US$4.27 to US$5.22. This gives investors a clear read on top line scale and earnings power as they assess...